nimodipine has been researched along with Cerebral Small Vessel Diseases in 3 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Cerebral Small Vessel Diseases: Pathological processes or diseases where cerebral MICROVESSELS show abnormalities. They are often associated with aging, hypertension and risk factors for lacunar infarcts (see LACUNAR INFARCTION); LEUKOARAIOSIS; and CEREBRAL HEMORRHAGE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CONIVaD (choline alphoscerate and nimodipine in vascular dementia) is a pilot, single-center, double-blinded, randomized trial aimed to assess whether the association of choline alphoscerate and nimodipine is more effective than nimodipine alone in reducing cognitive decline in patients with SVD and mild-to-moderate cognitive impairment." | 5.34 | Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial. ( Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2020) |
| " Fourteen patients (22%) dropped out for reasons including consent withdrawal (n = 9), adverse reactions (n = 4), and stroke (n = 1)." | 3.01 | Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial. ( Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2021) |
| " In the observation group, patients were given rosuvastatin in combination with nimodipine, and other patients were given nimodipine in the control group." | 1.51 | Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. ( Liu, N; Yang, C; Zhang, J, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Salvadori, E | 2 |
| Poggesi, A | 2 |
| Donnini, I | 2 |
| Rinnoci, V | 2 |
| Chiti, G | 2 |
| Squitieri, M | 2 |
| Tudisco, L | 2 |
| Fierini, F | 2 |
| Melone, A | 2 |
| Pescini, F | 2 |
| Pantoni, L | 2 |
| Zhang, J | 1 |
| Liu, N | 1 |
| Yang, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment[NCT03228498] | Phase 2 | 62 participants (Actual) | Interventional | 2017-05-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for nimodipine and Cerebral Small Vessel Diseases
| Article | Year |
|---|---|
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Topics: Aged; Aged, 80 and over; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Glycerylphosphorylch | 2021 |
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial.
Topics: Aged; Calcium Channel Blockers; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia, Vas | 2020 |
1 other study available for nimodipine and Cerebral Small Vessel Diseases
| Article | Year |
|---|---|
Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease.
Topics: Activities of Daily Living; Aged; C-Reactive Protein; Cerebral Small Vessel Diseases; Cholesterol; C | 2019 |